Literature DB >> 18731132

TREATMENT OF DISEASES OF VIRUS ORIGIN.

M D Eaton.   

Abstract

Keywords:  VIRUSES/diseases

Mesh:

Year:  1946        PMID: 18731132      PMCID: PMC1642717     

Source DB:  PubMed          Journal:  Calif Med        ISSN: 0008-1264


× No keyword cloud information.
  7 in total

1.  Can Chemotherapy Be Extended to Include the Intracellular Disease Agents?

Authors:  S Mudd
Journal:  J Bacteriol       Date:  1945-06       Impact factor: 3.490

2.  CHEMICAL, CLINICAL, AND IMMUNOLOGICAL STUDIES ON THE PRODUCTS OF HUMAN PLASMA FRACTIONATION. X. THE CONCENTRATIONS OF CERTAIN ANTIBODIES IN GLOBULIN FRACTIONS DERIVED FROM HUMAN BLOOD PLASMA.

Authors:  J F Enders
Journal:  J Clin Invest       Date:  1944-07       Impact factor: 14.808

3.  STUDIES ON PRIMARY ATYPICAL PNEUMONIA. II. OBSERVATIONS CONCERNING THE RELATIONSHIP OF A NON-HEMOLYTIC STREPTOCOCCUS TO THE DISEASE.

Authors:  L Thomas; G S Mirick; E C Curnen; J E Ziegler; F L Horsfall
Journal:  J Clin Invest       Date:  1945-03       Impact factor: 14.808

4.  STUDIES ON PRIMARY ATYPICAL PNEUMONIA. I. CLINICAL FEATURES AND RESULTS OF LABORATORY INVESTIGATIONS.

Authors:  E C Curnen; G S Mirick; J E Ziegler; L Thomas; F L Horsfall
Journal:  J Clin Invest       Date:  1945-03       Impact factor: 14.808

5.  CHEMICAL, CLINICAL, AND IMMUNOLOGICAL STUDIES ON THE PRODUCTS OF HUMAN PLASMA FRACTIONATION. I. THE CHARACTERIZATION OF THE PROTEIN FRACTIONS OF HUMAN PLASMA.

Authors:  E J Cohn; J L Oncley; L E Strong; W L Hughes; S H Armstrong
Journal:  J Clin Invest       Date:  1944-07       Impact factor: 14.808

6.  CHEMICAL, CLINICAL, AND IMMUNOLOGICAL STUDIES ON THE PRODUCTS OF HUMAN PLASMA FRACTIONATION. XI. THE USE OF CONCENTRATED NORMAL HUMAN SERUM GAMMA GLOBULIN (HUMAN IMMUNE SERUM GLOBULIN) IN THE PROPHYLAXIS AND TREATMENT OF MEASLES.

Authors:  J Stokes; E P Maris; S S Gellis
Journal:  J Clin Invest       Date:  1944-07       Impact factor: 14.808

7.  A SEARCH FOR VIRUS-INACTIVATING SUBSTANCES AMONG MICROORGANISMS.

Authors:  D Jones; F R Beaudette; W B Geiger; S A Waksman
Journal:  Science       Date:  1945-06-29       Impact factor: 47.728

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.